Endothelial Control of Vasomotor Tone: The Kidney Perspective

Seminars in Nephrology

Volumn 32, Issue 2, 2012, Pages 156-166

  Lamas, Santiago ^a   Rodríguez Puyol, Diego ^b  

^a Section of Nephrology   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Endothelial activation; Endothelial dysfunction; Endothelin; Nitric oxide; Prostacyclin

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN; ENDOTHELIN 1; NATRIURETIC PEPTIDE TYPE C; NITRIC OXIDE; PROSTACYCLIN;

ARTERIAL PRESSURE; ARTICLE; BIOACCUMULATION; BLOOD PRESSURE REGULATION; BLOOD VESSEL FUNCTION; BLOOD VESSEL TONE; CELL DAMAGE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ENVIRONMENTAL FACTOR; FLOW RATE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY BLOOD VESSEL; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY STRUCTURE; KIDNEY VASCULAR RESISTANCE; MICROVASCULAR ENDOTHELIAL CELL; MOLECULAR DYNAMICS; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASOMOTOR REFLEX;

ANIMALS; BLOOD PRESSURE; CYCLIC GMP; ENDOTHELIAL CELLS; ENDOTHELIN-1; EPOPROSTENOL; HUMANS; KIDNEY; NITRIC OXIDE; RENAL CIRCULATION; RENAL INSUFFICIENCY; VASOMOTOR SYSTEM;

EID: 84862078166     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.02.002     Document Type: Article

References (89)

1. Vanhoutte P.M., Shimokawa H., Tang E.H., Feletou M. Endothelial dysfunction and vascular disease. Acta Physiol (Oxf) 2009, 196:193-222.
2. Rabelink T.J., de Boer H.C., van Zonneveld A.J. Endothelial activation and circulating markers of endothelial activation in kidney disease. Nat Rev Nephrol 2010, 6:404-414.
3. Norel X. Prostanoid receptors in the human vascular wall. ScientificWorldJournal 2007, 7:1359-1374.
4. Flavahan N.A. Balancing prostanoid activity in the human vascular system. Trends Pharmacol Sci 2007, 28:106-110.
5. Nasrallah R., Hebert R.L. Prostacyclin signaling in the kidney: implications for health and disease. Am J Physiol Renal Physiol 2005, 289:F235-F246.
6. Ponnuchamy B., Khalil R.A. Cellular mediators of renal vascular dysfunction in hypertension. Am J Physiol Regul Integr Comp Physiol 2009, 296:R1001-R1018.
7. Vanhoutte P.M. COX-1 and vascular disease. Clin Pharmacol Ther 2009, 86:212-215.
8. Flammer A.J., Luscher T.F. Human endothelial dysfunction: EDRFs. Pflugers Arch 2010, 459:1005-1013.
9. Gryglewski R.J., Palmer R.M., Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986, 320:454-456.
10. Ignarro L.J., Buga G.M., Wood K.S., Byrns R.E., Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987, 84:9265-9269.
11. Palmer R.M., Ferrige A.G., Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987, 327:524-526.
12. Palmer R.M., Ashton D.S., Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988, 333:664-666.
13. Stuehr D.J., Santolini J., Wang Z.Q., Wei C.C., Adak S. Update on mechanism and catalytic regulation in the NO synthases. J Biol Chem 2004, 279:36167-36170.
14. Zhang Q., Malik P., Pandey D., Gupta S., Jagnandan D., de Chantemele E.B., et al. Paradoxical activation of endothelial nitric oxide synthase by NADPH oxidase. Arterioscler Thromb Vasc Biol 2008, 28:1627-1633.
15. Oess S., Icking A., Fulton D., Govers R., Müller-Esterl W. Subcellular targeting and trafficking of nitric oxide synthases. Biochem J 2006, 396:401-409.
16. Dudzinski D.M., Igarashi J., Greif D., Michel T.M. The regulation and pharmacology of endothelial nitric oxide synthases. Ann Rev Pharmacol Toxicol 2006, 46:235-276.
17. Fang F.C. Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat Rev Microbiol 2004, 2:820-832.
18. Cary S.P., Winger J.A., Derbyshire E.R., Marletta M.A. Nitric oxide signaling: no longer simply on or off. Trends Biochem Sci 2006, 31:231-239.
19. Hofmann F. The biology of cyclic GMP-dependent protein kinases. J Biol Chem 2005, 280:1-4.
20. Hofmann F., Feil R., Kleppisch T., Schlossmann J. Function of cGMP-dependent protein kinases as revealed by gene deletion. Physiol Rev 2006, 86:1-23.
21. Somlyo A.P., Somlyo A.V. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 2003, 83:1325-1358.
22. Burgoyne J.R., Madhani M., Cuello F., Charles R.L., Brennan J.P., Schroder E., et al. Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science 2007, 317:1393-1397.
23. Casteel D.E., Zhang T., Zhuang S., Pilz R.B. cGMP-dependent protein kinase anchoring by IRAG regulates its nuclear translocation and transcriptional activity. Cell Signal 2008, 20:1392-1399.
24. Yanagisawa M., Kurihara H., Kimura S., Tomobe Y., Kobayashi M., Mitsui Y., et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988, 332:411-415.
25. Miyauchi T., Masaki T. Pathophysiology of endothelin in the cardiovascular system. Annu Rev Physiol 1999, 61:391-415.
26. Lagares D., Garcia-Fernandez R.A., Jimenez C.L., Magan-Marchal N., Busnadiego O., Lamas S., et al. Endothelin 1 contributes to the effect of transforming growth factor beta1 on wound repair and skin fibrosis. Arthritis Rheum 2010, 62:878-889.
27. Hirata Y., Emori T., Eguchi S., Kanno K., Imai T., Ohta K., et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993, 91:1367-1373.
28. Thorin E., Webb D.J. Endothelium-derived endothelin-1. Pflugers Arch 2010, 459:951-958.
29. Lavallee M., Takamura M., Parent R., Thorin E. Crosstalk between endothelin and nitric oxide in the control of vascular tone. Heart Fail Rev 2001, 6:265-276.
30. Virdis A., Ghiadoni L., Taddei S. Human endothelial dysfunction: EDCFs. Pflugers Arch 2010, 459:1015-1023.
31. Basso N., Terragno N.A. History about the discovery of the renin-angiotensin system. Hypertension 2001, 38:1246-1249.
32. Tigerstedt R., Bergman P.G. Niere und Kreislauf. Scand Arch Physiol 1898, 8:223-271.
33. Lavoie J.L., Sigmund C.D. Minireview: overview of the renin-angiotensin system-an endocrine and paracrine system. Endocrinology 2003, 144:2179-2183.
34. Carmines P.K., Fleming J.T. Control of the renal microvasculature by vasoactive peptides. FASEB J 1990, 4:3300-3309.
35. Dibona G.F. Prostaglandins and nonsteroidal antiinflammatory drugs-effects on renal hemodynamics. Am J Med 1986, 80:12-21.
36. Fitzgibbon W.R., Ploth D.W., Margolius H.S. Kinins as vasoactive peptides. Curr Opin Nephrol Hypertens 1993, 2:283-290.
37. King A.J., Brenner B.M. Endothelium-derived vasoactive factors and the renal vasculature. Am J Physiol 1991, 260:R653-R662.
38. Kon V., Ichikawa I. Hormonal regulation of glomerular filtration. Ann Rev Med 1985, 36:515-531.
39. Satchell S.C., Braet F. Glomerular endothelial cell fenestrations: an integral component of the glomerular filtration barrier. Am J Physiol Renal Physiol 2009, 296:F947-F956.
40. Kamanna V.S., Pai R., Ha H., Kirschenbaum M.A., Roh D.D. Oxidized low-density lipoprotein stimulates monocyte adhesion to glomerular endothelial cells. Kidney Int 1999, 55:2192-2202.
41. Cai G.Y., Chen X.M., Fu B., Lu Y. Activation of gelatinases by fibrin is PA/plasmin system-dependent in human glomerular endothelial cells. Mol Cell Biochem 2005, 277:171-179.
42. Marsden P.A., Brock T.A., Ballermann B.J. Glomerular endothelial cells respond to calcium mobilizing agonists with release of EDRF. Am J Physiol 1990, 258:F1295-F1303.
43. Marsden P.A., Dorfman D.M., Collins T., Brenner B.M., Orkin S.H., Ballermann B.J. Regulated expression of endothelin-1 in glomerular capillary endothelial cells. Am J Physiol 1991, 261:F117-F125.
44. Nitta K., Simonson M.S., Dunn M.J. The regulation and role of prostaglandin biosynthesis in cultured bovine glomerular endothelial cells. J Am Soc Nephrol 1991, 2:156-163.
45. Satchell S.C., Anderson K.L., Mathieson P.W. Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol 2004, 15:566-574.
46. Woolf A.S., Gnudi L., Long D.A. Roles of angiopoietins in kidney development and disease. J Am Soc Nephrol 2009, 20:239-244.
47. Adler S., Eng B. Integrin receptors and function on cultured glomerular endothelial cells. Kidney Int 1993, 44:278-284.
48. Mizutani M., Okuda Y., Yamaoka T., Tsukahara K., Isaka M., Bannai C., et al. High glucose and hyperosmolarity increase platelet-derived growth factor messenger RNA levels in cultured human vascular endothelial cells. Biochem Biophys Res Commun 1992, 187:664-669.
49. Ochi H., Masuda J., Gimbrone M.A. Hyperosmotic stimuli inhibit VCAM-1 expression in cultured endothelial cells via effects on interferon regulatory factor-1 expression and activity. Eur J Immunol 2002, 32:1821-1831.
50. Gabbai F.B., Blantz R.C. Role of nitric oxide in renal hemodynamics. Semin Nephrol 1999, 19:242-250.
51. Deng A.H., Baylis C. Locally produced EDRF controls preglomerular resistance and ultrafiltration coefficient. Am J Physiol 1993, 264:F212-F215.
52. Ito S., Arima S., Ren Y.L., Juncos L.A., Carretero O.A. Endothelium-derived relaxing factor, nitric oxide modulates angiotensin-II action in the isolated microperfused afferent but not efferent arteriole. J Clin Invest 1993, 91:2012-2019.
53. Raij L., Shultz P.J. Endothelium-derived relaxing factor, nitric oxide effects on and production by mesangial cells and the glomerulus. J Am Soc Nephrol 1993, 3:1435-1441.
54. Guzman N.J., Fang M.Z., Tang S.S., Ingelfinger J.R., Garg L.C. Autocrine inhibition of Na+/K+-ATPase by nitric oxide in mouse proximal tubule epithelial cells. J Clin Invest 1995, 95:2083-2088.
55. Ortiz P.A., Garvin J.L. NO inhibits NaCl absorption by rat thick ascending limb through activation of cGMP-stimulated phosphodiesterase. Hypertension 2001, 37:467-471.
56. Stoos B.A., Carretero O.A., Farhy R.D., Scicli G., Garvin J.L. Endothelium-derived relaxing factor inhibits transport and increases cGMP content in cultured mouse cortical collecting duct cells. J Clin Invest 1992, 89:761-765.
57. Morishita T., Tsutsui M., Shimokawa H., Sabanai K., Tasaki H., Suda O., et al. Nephrogenic diabetes insipidus in mice lacking all nitric oxide synthase isoforms. Proc Natl Acad Sci U S A 2005, 102:10616-10621.
58. Adler S., Huang H., Loke K.E., Xu X.B., Tada H., Laumas A., et al. Endothelial nitric oxide synthase plays an essential role in regulation of renal oxygen consumption by NO. Am J Physiol Renal Physiol 2001, 280:F838-F843.
59. Plato C.F., Shesely E.G., Garvin J.L. eNOS mediates L-arginine-induced inhibition of thick ascending limb chloride flux. Hypertension 2000, 35:319-323.
60. Shesely E.G., Maeda N., Kim H.S., Desai K.M., Krege J.H., Laubach V.E., et al. Elevated blood pressures in mice lacking endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1996, 93:13176-13181.
61. Badr K.F., Murray J.J., Breyer M.D., Takahashi K., Inagami T., Harris R.C. Mesangial cells, glomerular and renal vascular responses to endothelin in the rat kidney. Elucidation of signal transduction pathways. J Clin Invest 1989, 83:336-342.
62. Marsden P.A., Brenner B.M. Nitric oxide and endothelins-novel autocrine paracrine regulators of the circulation. Semin Nephrol 1991, 11:169-185.
63. Perico N., Cornejo R.P., Benigni A., Malanchini B., Ladny J.R., Remuzzi G. Endothelin induces diuresis and natriuresis in the rat by acting on proximal tubular cells through a mechanism mediate by lipoxygenase products. J Am Soc Nephrol 1991, 2:57-69.
64. Kohan D.E. The renal medullary endothelin system in control of sodium and water excretion and systemic blood pressure. Curr Opin Nephrol Hypertens 2006, 15:34-40.
65. Pan L., Gross K.W. Transcriptional regulation of renin-an update. Hypertension 2005, 45:3-8.
66. Nasrallah R., Clark J., Hebert R.L. Prostaglandins in the kidney: developments since Y2K. Clin Sci 2007, 113:297-311.
67. Murata T., Ushikubi F., Matsuoka T., Hirata M., Yamasaki A., Sugimoto Y., et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 1997, 388:678-682.
68. Fujino T., Nakagawa N., Yuhki K., Hara A., Yamada T., Takayama K., et al. Decreased susceptibility to renovascular hypertension in mice lacking the prostaglandin I-2 receptor IP. J Clin Invest 2004, 114:805-812.
69. Suga S., Nakao K., Itoh H., Komatsu Y., Ogawa Y., Hama N., et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of vascular natriuretic peptide synthesis. J Clin Invest 1992, 90:1145-1149.
70. Terada Y., Tomita K., Nonoguchi H., Yang T.X., Marumo F. PCR localization of C-type natriuretic peptide and B-type receptor messenger RNA in rat nephron segments. Am J Physiol 1994, 267:F215-F222.
71. Hirsch J.R., Meyer M., Magert H.J., Forssmann W.G., Mollerup S., Herter P., et al. cGMP-dependent and -independent inhibition of a K+ conductance by natriuretic peptides: molecular and functional studies in human proximal tubule cells. J Am Soc Nephrol 1999, 10:472-480.
72. Amin J., Carretero O.A., Ito S. Mechanisms of action of atrial natriuretic factor and C-type natriuretic peptide. Hypertension 1996, 27:684-687.
73. Pham I., Sediame S., Maistre G., Roudot Thoraval F., Chabrier P.E., Carayon A., et al. Renal and vascular effects of C-type and atrial natriuretic peptides in humans. Am J Physiol Regul Integr Comp Physiol 1997, 273:R1457-R1464.
74. Deanfield J.E., Halcox J.P., Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007, 115:1285-1295.
75. Thomas S.R., Witting P.K., Drummond G.R. Redox control of endothelial function and dysfunction: molecular mechanisms and therapeutic opportunities. Antioxid Redox Signal 2008, 10:1713-1765.
76. Amiri F., Virdis A., Neves M.F., Iglarz M., Seidah N.G., Touyz R.M., et al. Endothelium-restricted overexpression of human endothelin-1 causes vascular remodeling and endothelial dysfunction. Circulation 2004, 110:2233-2240.
77. Passauer J., Pistrosch F., Bussemaker E., Lassig G., Herbrig K., Gross P. Reduced agonist-induced endothelium-dependent vasodilation in uremia is attributable to an impairment of vascular nitric oxide. J Am Soc Nephrol 2005, 16:959-965.
78. Vallance P., Leone A., Calver A., Collier J., Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575.
79. Matsuguma K., Ueda S., Yamagishi S.I., Matsumoto Y., Kaneyuki U., Shibata R., et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol 2006, 17:2176-2183.
80. Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. Nat Clin Pract Nephrol 2006, 2:209-220.
81. Vaziri N.D. Oxidative stress in uremia: nature, mechanisms, and potential consequences. Semin Nephrol 2004, 24:469-473.
82. Koyama H., Nishzawa Y., Morii H., Tabata T., Inoue T., Yamaji T. Plasma endothelin levels in patients with uremia. Lancet 1989, 1:991-992.
83. Farkas K., Nemcsik J., Kolossvary E., Jarai Z., Nadory E., Farsang C., et al. Impairment of skin microvascular reactivity in hypertension and uraemia. Nephrol Dial Transplant 2005, 20:1821-1827.
84. D'Amours M., Chbinou N., Beaudoin J., Lebel M., Lariviere R. Increased ET-1 and reduced ETB receptor expression in uremic hypertensive rats. Clin Exp Hypertens 2010, 32:61-69.
85. Lariviere R., Moreau C., Rodrigue M.E., Lebel M. Thromboxane blockade reduces blood pressure and progression of renal failure independent of endothelin-1 in uremic rats. Prostaglandins Leukot Essent Fatty Acids 2004, 71:103-109.
86. Muthing J., Schweppe C.H., Karch H., Friedrich A.W. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Thromb Haemost 2009, 101:252-264.
87. Bitzan M.M., Wang Y., Lin J., Marsden P.A. Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J Clin Invest 1998, 101:372-382.
88. Rodriguez de Cordoba S. aHUS: a disorder with many risk factors. Blood 2010, 115:158-160.
89. Manea M., Karpman D. Molecular basis of ADAMTS13 dysfunction in thrombotic thrombocytopenic purpura. Pediatr Nephrol 2009, 24:447-458.